Bacteromic, a subsidiary of the Scope Fluidics Group listed on the Warsaw Stock Exchange (GPW), has signed a two-year framework distribution agreement with the Turkish company Mefamed, a distributor of medical devices. The agreement covers the distribution and promotion of the BACTEROMIC system in the Turkish market and represents another step in the development of the project.
“The signing of a framework distribution agreement with Mefamed marks an important milestone in the commercialization of the BACTEROMIC system. Mefamed is an experienced distributor of medical devices, specializing in innovative technologies and working with international brands. We are confident that combining our technology with Mefamed’s distribution expertise will provide a solid foundation for the further development of the BACTEROMIC project and for preparing it to enter additional foreign markets,” says Piotr Garstecki, President of Scope Fluidics.
The launch of distribution of the BACTEROMIC system in the Turkish market will be possible once Mefamed completes the registration process in accordance with local regulations. The procedure is expected to take no longer than one month from the date Bacteromic submits the required documentation, including the IVDR certificate, which Bacteromic expects to obtain in early 2026.
The next stage will involve Mefamed establishing commercial relationships with end-customers of the BACTEROMIC system, including entering into agreements with private and public diagnostic laboratories.
BACTEROMIC – key information
Scope Fluidics owns the dedicated subsidiary Bacteromic sp. z o.o., which was established to develop the BACTEROMIC system – a rapid, automated system for testing bacterial susceptibility to antibiotics (Antibiotic Susceptibility Testing, AST). The system provides precise information on which clinically relevant antibiotics are likely to be most effective in treating a bacterial infection.
The system is characterized by high versatility and a broad range of potential applications, as well as high-cost efficiency for both the analyzer and the disposable cartridges. BACTEROMIC has the potential to position itself as the gold standard among existing solutions as well as new innovative AST technologies, meeting the needs of all stakeholders involved in antimicrobial resistance: speed, comprehensiveness of information, high throughput, process automation, ease of use, and cost-effectiveness.
The system consists of a laboratory analyzer (and a smaller filling device used for automated sample loading into the cartridge) and disposable Panels, which can accommodate up to 60 antibiotics, each in several to a dozen dilutions. This enables the precise determination of the Minimum Inhibitory Concentration (MIC). The system is also highly flexible in terms of potential applications, allowing for the use of the current cartridge architecture with various types of samples.
